Wuhan Hiteck Biological Pharma Co.,Ltd
SHZ: 300683.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Wen Xian
- Employees
- 1,520
- Headquarters
- Wuhan, China
- IPO year
- 2017
- Market cap
- CN¥4.8B
- Website
- https://www.hiteck.com.cn
Loading 300683…
Loading profile data…Frequently asked questions about 300683
What does Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) do?
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an...
Where does 300683.SZ trade?
Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) trades on the Shenzhen Stock Exchange.
What sector is 300683.SZ in?
Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Wuhan Hiteck Biological Pharma Co.,Ltd?
Wen Xian is the chief executive officer of Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ).
Where is Wuhan Hiteck Biological Pharma Co.,Ltd headquartered?
Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in China.
Does 300683.SZ pay a dividend?
Yes — Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) paid a trailing twelve-month dividend of CNY 0.13 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 300683.SZ go public?
Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) completed its initial public offering in 2017.